Multitude Therapeutics Inc.
Clinical trials sponsored by Multitude Therapeutics Inc., explained in plain language.
-
Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
Disease control Not yet recruitingThis trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works bette…
Phase: PHASE2, PHASE3 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for advanced colon cancer: experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called AMT-676 combined with standard chemotherapy and targeted therapy for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow the disease. About 180 a…
Phase: PHASE2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC